{
    "clinical_study": {
        "@rank": "68791", 
        "acronym": "RDNP-2012-01", 
        "arm_group": [
            {
                "arm_group_label": "Renal Denervation Group", 
                "arm_group_type": "Experimental", 
                "description": "participants randomised to undergo the renal denervation procedure"
            }, 
            {
                "arm_group_label": "Usual care", 
                "arm_group_type": "No Intervention", 
                "description": "participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study investigating the effectiveness of renal denervation in lowering blood\n      pressure in people whose blood pressure is not adequately controlled despite treatment with\n      3 or more blood pressure lowering drugs. The study is designed to compare the effects of\n      renal denervation to a usual care group receiving additional blood pressure lowering drugs."
        }, 
        "brief_title": "Renal Denervation for Resistant Hypertension", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "detailed_description": {
            "textblock": "Previous studies have shown that the renal denervation procedure is safe and effective in\n      reducing blood pressure in patients with resistant hypertension.   A total of 100\n      participants with uncontrolled blood pressure, treated with three or more blood pressure\n      lowering medications will be recruited into the study. Patients will be assigned to one (1)\n      of two (2) groups with the aim of attaining blood pressure control. Participants in group 1\n      will be assigned to renal denervation, participants in group 2 will receive additional\n      antihypertensive medication according to current guidelines and best practice in an attempt\n      to reach blood pressure targets."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  systolic BP \u2265140mmHg or \u2265130mmHg for patients with diabetes\n\n          -  concurrent treatment with \u22653 anti-hypertensive drugs\n\n        Exclusion Criteria:\n\n          -  renal artery anatomy ineligible for treatment\n\n          -  eGFR <15mL/min/1.73m2 (using MDRD calculation)\n\n          -  female participants of childbearing potential must have negative pregnancy test prior\n             to treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01865240", 
            "org_study_id": "008/12", 
            "secondary_id": "NHMRC"
        }, 
        "intervention": {
            "arm_group_label": "Renal Denervation Group", 
            "description": "Renal Denervation Catheter", 
            "intervention_name": "Renal Denervation", 
            "intervention_type": "Device", 
            "other_name": "Symplicity Renal Denervation Catheter"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "renal denervation", 
            "blood pressure", 
            "cardiovascular risk", 
            "target organ damage", 
            "sympathetic activity"
        ], 
        "lastchanged_date": "December 16, 2013", 
        "location": {
            "contact": {
                "email": "markus.schlaich@bakeridi.edu.au", 
                "last_name": "Markus P Schlaich, MD", 
                "phone": "+61 3 8532 1502"
            }, 
            "facility": {
                "address": {
                    "city": "Melbourne", 
                    "country": "Australia", 
                    "state": "Victoria", 
                    "zip": "3004"
                }, 
                "name": "Baker IDI Heart & Diabetes Inst"
            }, 
            "investigator": {
                "last_name": "Markus P Schlaich, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "2", 
        "official_title": "Renal Denervation for Resistant Hypertension", 
        "overall_contact": {
            "email": "markus.schlaich@bakeridi.edu.au", 
            "last_name": "Markus P Schlaich, MD", 
            "phone": "+61 3 8532 1502"
        }, 
        "overall_contact_backup": {
            "email": "petra.marusic@bakeridi.edu.au", 
            "last_name": "Petra Marusic, B.App.Sci", 
            "phone": "+61 3 8532 1734"
        }, 
        "overall_official": {
            "affiliation": "Baker IDI Heart & Diabetes Institute", 
            "last_name": "Markus Schlaich, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "percentage of patients to achieve BP target  (BP <140/90mmHg, or <130/80mmHg in diabetic patients) at 6 months post procedure", 
            "measure": "blood pressure control", 
            "safety_issue": "No", 
            "time_frame": "6 months post procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01865240"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "number of drugs required to reach blood pressure target", 
                "measure": "number of drugs required to reach blood pressure target", 
                "safety_issue": "No", 
                "time_frame": "baseline to 6 months"
            }, 
            {
                "description": "time to achieve blood pressure target", 
                "measure": "time to achieve blood pressure target", 
                "safety_issue": "No", 
                "time_frame": "baseline to 6 months"
            }, 
            {
                "description": "Changes in muscle sympathetic nerve activity (MSNA), renal and whole body NE spillover", 
                "measure": "Change in markers of sympathetic nerve activity", 
                "safety_issue": "No", 
                "time_frame": "baseline to 6 months"
            }, 
            {
                "description": "Change in Left Ventricular mass index, ejection fraction, diastolic filling as assessed by echocardiogram", 
                "measure": "Change in Left Ventricular Structure and Function", 
                "safety_issue": "No", 
                "time_frame": "baseline to 6 months"
            }, 
            {
                "description": "Change in Quality of Life as assessed by relevant questionnaires", 
                "measure": "Change in Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "baseline to 6 months"
            }, 
            {
                "description": "Plasma renin activity, aldosterone, eGFR, UACR, inflammatory markers, 24hour urinary creatinine clearance, sodium, fasting glucose, fasting insulin, c-peptide, HOMA index, lipid profile", 
                "measure": "Serum and Urine Biochemistry", 
                "safety_issue": "Yes", 
                "time_frame": "baseline to 6 months"
            }, 
            {
                "description": "Change in markers of arterial stiffness incduing AI and PWV", 
                "measure": "Change in markers of arterial stiffness", 
                "safety_issue": "No", 
                "time_frame": "baseline to 6 months"
            }
        ], 
        "source": "Baker IDI Heart and Diabetes Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Baker IDI Heart and Diabetes Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}